Guy Van Meter joins Adimab
This article was originally published in Scrip
Adimab, a US biotechnology company developing an integrated yeast-based antibody discovery and maturation platform, has appointed Guy Van Meter senior director, head of business development. He joins from Pfizer, where he was involved in new business initiatives around RNAi therapeutics and regenerative medicine for Pfizer's Biotherapeutics and Bioinnovation Center in San Francisco.
You may also be interested in...
The EU has published an action plan that is intended to upgrade the bloc’s intellectual property framework while ensuring that goods such as medicines and vaccines are made as widely available as possible. The initiative is part of wide-ranging plans to support member states’ recovery from the pandemic crisis and help ensure the EU’s resilience to future health threats.
Execs On The Move: New CEO For Humacyte; Internal Moves At Trinity Biotech, CVRx, Oventus Medical And Cancer Genetics
Trinity Biotech's new CFO is an internal move; Humacyte replaces CEO; chief strategy officer role for former CVRx CFO; and more.
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.